The Importance of Clotho Proteinin the Development of Chronic Kidney Disease in the Context of Chronic Heart Failure
Keywords:
Clotho protein, chronic kidney disease, chronic heart failure, antioxidant system, fibroblast–23.Abstract
The review article presents current research data on the importance of the Clotho proteinin the pathogenesis of chronic kidney disease in the context of chronic heart failure. The relationship of the Clotho protein with fibroblast growth factor–23 and its antioxidant properties is presented. It has been describedthat the α–clotho protein reduces the development of endothelial dysfunction and atherosclerosis by reducing oxidative stress and inflammation.
References
Hatamizadeh P., Fonarow G.C., Budoff M.J. et al. Cardiorenalsyndrome: pathophysiology and potential targets for clinicalmanagement. Nat Rev Nephrol. 2013; 9 (2): 99-111.;
Нежданов К.С., Милованова Л.Ю., Стрижаков Л.А., Краснова Т.Н. Кардиоренальные синдромы: история и современность. Терапевтический архив. 2023;95(6):521–525. DOI: 10.26442/00403660.2023.06.202234© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
Nabeshima Y. The discovery of -Klotho and FGF23 unveiled new insight into calcium and phosphate homeostasis // Cell. Mol. Life Sci. — 2008 Oct. — 65(20). — 3218-30. doi: 10.1007/ s00018-008-8177-0.
Forster R.E., Jurutka P.W., Hsieh J.C. et al. Vitamin D receptor controls expression of the anti-aging klotho gene in mouse and human renal cells // Biochem. Biophys. Res. Commun. — 2011 Oct 28. — 414(3). — 557-62. doi: 10.1016/j. bbrc.2011.09.117
Hruska KA, Sugatani T, Agapova O, Fang Y. The chronic kidney disease - Mineral bone disorder (CKD-MBD): Advances in pathophysiology. Bone.2017;100:80–6.;
Chen Z, Qureshi AR, Ripsweden J, Wennberg L, Heimburger O, Lindholm B,Barany P, Haarhaus M, Brismar TB, Stenvinkel P. Vertebral bone densityassociates with coronary artery calcification and is an independent predictorof poor outcome in end-stage renal disease patients. Bone. 2016;92:50–7.
Neyra JA, Hu MC. Potential application of klotho in human chronic kidneydisease. Bone. 2017;100:41–49.;
Takenaka T, Inoue T, Miyazaki T, Hayashi M, Suzuki H. Xeno-Klotho Inhibits Parathyroid Hormone Signaling. J Bone Miner Res. 2016;31(2):455–62.;
Kuro OM. The FGF23 and Klotho system beyond mineral metabolism.ClinExpNephrol. 2017;21(Suppl 1):64–9.;
Salanova Villanueva L, Sanchez Gonzalez C, Sanchez Tomero JA, Aguilera A,Ortega Junco E. Bone mineral disorder in chronic kidney disease: Klothoand FGF23; cardiovascular implications. Nefrologia. 2016;36(4):368–75.
Shimamura Y, Hamada K, Inoue K, Ogata K, Ishihara M, Kagawa T, Inoue M, Fujimoto S, Ikebe M, Yuasa K, et al. Serum levels of soluble secreted alpha-Klothoare decreased in the early stages of chronic kidney disease, making it a probablenovel biomarker for early diagnosis. Clin Exp Nephrol. 2012;16(5):722–9.;
Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C,Sales S, Farcomeni A, Mazzaferro S. Soluble alpha -Klotho Serum Levels inChronic Kidney Disease. Int J Endocrinol. 2015;2015:872193.
Tan SJ, Smith ER, Holt SG, Hewitson TD, Toussaint ND. Soluble klotho maybe a marker of phosphate reabsorption. Clin Kidney J. 2017;10(3):397–404.
Webster AC, Nagler EV, Morton RL, Masson P. Chronic Kidney Disease. Lancet. 2017;389(10075):1238–52.
Rotondi S, Pasquali M, Tartaglione L, Muci ML, Mandanici G, Leonangeli C, Sales S, Farcomeni A, Mazzaferro S. Soluble alpha -Klotho Serum Levels in Chronic Kidney Disease. Int J Endocrinol. 2015;2015:872193.;
Tan SJ, Smith ER, Holt SG, Hewitson TD, Toussaint ND. Soluble klotho maybe a marker of phosphate reabsorption. Clin Kidney J. 2017;10(3):397–404.;
Koh N, Fujimori T, Nishiguchi S, Tamori A, Shiomi S, Nakatani T, Sugimura K,Kishimoto T, Kinoshita S, Kuroki T, et al. Severely reduced production ofklotho in human chronic renal failure kidney. Biochem Biophys ResCommun. 2001;280(4):1015–20.;
Asai O, Nakatani K, Tanaka T, Sakan H, Imura A, Yoshimoto S, Samejima K,Yamaguchi Y, Matsui M, Akai Y, et al. Decreased renal alpha-Klothoexpression in early diabetic nephropathy in humans and mice and itspossible role in urinary calcium excretion. Kidney Int. 2012;81(6):539–47.
Hu MC, Shi M, Zhang J, Quinones H, Griffith C, Kuro-o M, Moe OW. Klothodeficiency causes vascular calcification in chronic kidney disease. J Am SocNephrol. 2011;22(1):124–36.;
Akimoto T, Yoshizawa H, Watanabe Y, Numata A, Yamazaki T, Takeshima E, Iwazu K, Komada T, Otani N, Morishita Y, et al. Characteristics of urinary and serum soluble Klotho protein in patients with different degrees of chronic kidney disease. BMC Nephrol. 2012;13:155.
Kim HR, Nam BY, Kim DW, Kang MW, Han JH, Lee MJ, Shin DH, Doh FM, Koo HM, Ko KI, et al. Circulating alpha-klotho levels in CKD and relationship to progression. Am J Kidney Dis. 2013;61(6):899–909.
Pavik I, Jaeger P, Ebner L, Wagner CA, Petzold K, Spichtig D, Poster D, Wuthrich RP, Russmann S, Serra AL. Secreted Klotho and FGF23 in chronickidney disease Stage 1 to 5: a sequence suggested from a cross-sectionalstudy. Nephrol Dial Transplant. 2013;28(2):352–9.
Seiler S, Wen M, Roth HJ, Fehrenz M, Flugge F, Herath E, Weihrauch A, Fliser D, Heine GH. Plasma Klotho is not related to kidney function and does notpredict adverse outcome in patients with chronic kidney disease. Kidney Int.2013;83(1):121–8.
Yamazaki Y, Imura A, Urakawa I, Shimada T, Murakami J, Aono Y, Hasegawa H, Yamashita T, Nakatani K, Saito Y, et al. Establishment of sandwich ELISAfor soluble alpha-Klotho measurement: Age-dependent change of solublealpha-Klotho levels in healthy subjects. Biochem Biophys Res Commun. 2010;398(3):513–8.
